[ad_1]
Posted in:
Last week, the US Food and Drug Administration (FDA) admitted the drug Vitrakvi (Larotrectinib), which became the second most effective drug in the treatment of genetic mutations at the origin of the drug. appearance of cancerous tumors.
After Keytruda (pembrolizumab) in 2017 was approved to use to treat advanced solid tumors, the US Food and Drug Administration (FDA) approved Vitrakvi, one of the drugs the smartest targeting targeted cancer treatments.
Vitrakvi primarily targets cancerous tumors caused by genetic mutations of NTRK genes, regardless of the type or location of the tumor. These types of genetic mutations are not common but are encountered by oncologists in salivary gland cancer, thyroid cancer, lung cancer and soft tissue tumors.
Vitrakvi is suitable for children and adults with genetic mutations in the NTRK gene. This drug is used in tumors that have spread throughout the body and whose surgery has not been eradicated or has not responded. available treatments.
After three clinical trials involving 55 children and adults with solid tumors, the response rate for vitrakvi was 75%.
Vitrakvi is available on two bodies: the first in tablets or capsules, and the other a syrup for children in particular, but the monthly cost of treatment up to 32,800 dollars.
Tamer Abdel Gawad, Radiology Consultant, Advanced Care Center for Diagnosis and Treatment of Oncology in the United Arab Emirates.
Source link
